In this report we look at the burden of cryptococcal meningitis, issues with current treatment regimens and future research directions.
Browsing: Fungal > Cryptococcal Meningitis
Take a look at our infographic to find out more about the burden of some common fungal infections and assess why the facts and figures are so uncertain.
Researchers have examined the complex interaction between environmental pressures and human virulence in Cryptococcus neoformans, demonstrating some variants associated with clinical isolates.
Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery (CO-ADD) discusses his work towards uncovering compounds with antibiotic potential and shares his thoughts on the best strategies to tackle antibiotic resistance moving forwards.
Researchers from Durham University have developed a new, simplified production process for a drug vital to treating cryptococcal meningitis; they hope this will reduce the drug’s cost and increase its availability in developing countries.
The most common cause of fungal meningitis for people with weak immune systems is Cryptococcus. This study aims to investigate the involvement of the autophagy protein 7 in the physiology and pathogenic potential of Cryptococcus neoformans.